{"id":598789,"date":"2022-05-05T19:56:01","date_gmt":"2022-05-05T19:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=598789"},"modified":"2022-05-05T19:56:01","modified_gmt":"2022-05-05T19:56:01","slug":"cataplexy-market-to-grow-rapidly-during-the-forecast-period-201932-estimates-delveinsight-key-companies-avadel-takeda-axsome-therapeutics-suven-life-sciences-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cataplexy-market-to-grow-rapidly-during-the-forecast-period-201932-estimates-delveinsight-key-companies-avadel-takeda-axsome-therapeutics-suven-life-sciences-and-others_598789.html","title":{"rendered":"Cataplexy Market to Grow Rapidly During the Forecast Period (2019-32) &#8211; Estimates DelveInsight | Key Companies &#8211; Avadel, Takeda, Axsome Therapeutics, Suven Life Sciences, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cataplexy Market to Grow Rapidly During the Forecast Period (2019-32) - Estimates DelveInsight | Key Companies - Avadel, Takeda, Axsome Therapeutics, Suven Life Sciences, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"Cataplexy Market to Grow Rapidly During the Forecast Period (2019-32) - Estimates DelveInsight | Key Companies - Avadel, Takeda, Axsome Therapeutics, Suven Life Sciences, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Cataplexy Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cataplexy Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Cataplexy market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Cataplexy Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/1524ebbbf49f1d0b679089bd6678d9df.jpg\" alt=\"Cataplexy Market\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cataplexy: An Overview<\/strong><\/p>\n<p style=\"text-align: justify;\"><em>Cataplexy is sudden and uncontrollable muscle weakness or paralysis that comes on during the day and is often triggered by strong emotions, such as excitement or laughter. The vast majority of people who experience cataplexy do so as a result of having type 1 narcolepsy, a chronic sleep and neurological disorder in which the brain has trouble properly controlling wake and sleep cycles. In very rare cases, cataplexy has been reported in individuals without narcolepsy. The cause of this circumstance remains unknown.<\/em><\/p>\n<p style=\"text-align: justify;\"><em>Both cataplexy and narcolepsy with cataplexy can be treated with medication and lifestyle changes. Medications cannot cure cataplexy, but they can help manage the symptoms. Furthermore, Sodium oxybate has been approved by the US FDA for the treatment of cataplexy.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cataplexy Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>In the study titled &ldquo;Clinical features and diagnosis of narcolepsy in adults&rdquo;, Scammell (2020) stated that NT1 (narcolepsy with cataplexy) was estimated to have a prevalence of 25 to 50 per 100,000 people. It was found to be equally common in men and women. The study also suggests that narcolepsy typically begins in the teens and early twenties, but occasionally occurs as early as five years of age or after 40 years of age.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em><em>Mirabile and Sharma (2020) in the study titled &ldquo;Cataplexy&rdquo;, stated that in the US, narcolepsy affects 1 in 2000 individuals with an equal distribution amongst the sexes. As per the study, symptom onset most frequently occurs during adolescence; however, diagnosis often gets delayed on average by 15 years.&nbsp;<\/em><\/em><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cataplexy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Cataplexy Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><em><strong>Cataplexy market size<\/strong> is expected to increase during the forecast period owing to the rise in the number of prevalent cases in the 7MM.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted <strong>Cataplexy market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives complete detail of the <strong>Cataplexy market trend<\/strong> for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cataplexy Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cataplexy Epidemiology Segmentation &#8211;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Prevalent Population of Cataplexy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Diagnosed Prevalent Population of Cataplexy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Treatable Cases of Cataplexy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cataplexy Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Cataplexy market<\/strong> or expected to get launched during the study period. The analysis covers Cataplexy market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers the <strong>Cataplexy Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cataplexy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/cataplexy-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cataplexy Therapeutics Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The Cataplexy market dynamic is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise efficient treatment options. The pipeline of Cataplexy possesses few potential key players and the launch of emerging therapies is expected during the forecast period.&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Cataplexy Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Avadel<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Takeda&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Axsome Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Suven Life Sciences<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cataplexy Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">AXS-12<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">SUVN-G3031<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tak-944<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">TAK-925<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">FT218<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp;&nbsp;<br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cataplexy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/cataplexy-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Cataplexy Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Cataplexy Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Cataplexy Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Cataplexy Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Cataplexy Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Cataplexy Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Cataplexy Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Cataplexy Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Cataplexy Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Cataplexy Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Cataplexy Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Cataplexy Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Cataplexy Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Cataplexy Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Cataplexy Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Cataplexy Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cataplexy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/cataplexy-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/stable-angina-market\">Stable Angina Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &#8220;<strong>Stable Angina Market<\/strong>&#8221; report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Stable Angina Market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cataplexy-market-to-grow-rapidly-during-the-forecast-period-201932-estimates-delveinsight-key-companies-avadel-takeda-axsome-therapeutics-suven-life-sciences-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +91 9568243403<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cataplexy-market-to-grow-rapidly-during-the-forecast-period-201932-estimates-delveinsight-key-companies-avadel-takeda-axsome-therapeutics-suven-life-sciences-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Cataplexy Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cataplexy Market size, share, and trends in the seven major market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cataplexy-market-to-grow-rapidly-during-the-forecast-period-201932-estimates-delveinsight-key-companies-avadel-takeda-axsome-therapeutics-suven-life-sciences-and-others_598789.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,405,417,406],"tags":[],"class_list":["post-598789","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/598789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=598789"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/598789\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=598789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=598789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=598789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}